Shopping Cart 0
Cart Subtotal
USD 0

Global Respiratory Drugs Market 2018-2024

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 3500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 4500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Respiratory disorders, which affect mechanisms of the respiratory system such as the lungs and airway, are a wide-ranging chronic disease with a diversity of underlying causes, ranging from inherited mutations to pathological inflammation. The respiratory disorders market is dominated by long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapies for chronic obstructive pulmonary disease (COPD) and asthma. These drugs stimulate muscles surrounding the bronchial tubes to suppress and open the airways.

 

Respiratory therapy area consists of signs that affect the lungs, bronchi, trachea, larynx, pharynx and nose in various ways, such as the scarring of lung tissue or the extreme production of mucus. Respiratory disease generally results in breathing difficulties, that can lead to troubles in sleep, wheezing, anxiety, and stress. During worse condition, shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders contrasts significantly across each indication and comprises factors such as environment, occupation, genetic predisposition, and aging.

 

Report Scope:

 

Report Category: Pharmacuticals / Healthcare

 

Therapy Type

Asthma

Chronic Obstructive Pulmonary Disease

Idiopathic Pulmonary Fibrosis

Cystic Fibrosis

End-user

Hospitals

Ambulatory Care

Others

Regions

North America

Europe

Asia Pacific

Rest of the World

Industry Outlook: Market Trends and Drivers, Restraints, and Opportunities

READ MORE

Table Of Content

Scope

Table of Contents

1 Industry Outlook 9

1.1 Industry Overview 9

1.2 Total Addressable Market 10

1.3 Industry Trends 10

2 Report Outline 12

2.1 Report Scope 12

2.2 Report Summary 12

2.3 Research Methodology 13

2.4 Report Assumptions 13

3 Market Snapshot 15

3.1 Market Definition-Infoholic Research 15

3.2 Segmented Addressable Market (SAM) 15

3.3 Importance of Respiratory Care 15

3.4 Trends of Respiratory Drugs Market 16

3.5 Related Markets 17

3.5.1 Oncology (Cancer) Drugs 17

3.5.2 Active pharmaceutical ingredients (APIs) 17

3.5.3 Over the counter drugs (OTC) 18

3.5.4 Diabetes Drugs 18

4 Market Outline 20

4.1 Pipeline Products of Respiratory Drugs by Major Companies 20

4.2 Market Segmentation 23

4.3 Porter 5(Five) Forces 24

4.4 PEST Analysis 25

5 Market Characteristics 26

5.1 Market Dynamics of Respiratory Drugs Market 26

5.1.1 Drivers 27

5.1.1.1 Increasing Aging Population 27

5.1.1.2 Rising prevalence of respiratory diseases 28

5.1.1.3 High prevalence of tobacco smoking 28

5.1.2 Opportunities 28

5.1.2.1 Supportive initiatives from government and other organizations 28

5.1.2.2 Huge pool of undiagnosed chronic obstructive pulmonary disease population 28

5.1.3 Restraints 29

5.1.3.1 Expiry of patents for blockbuster drugs 29

5.1.3.2 Complex drug development process 30

5.1.4 DRO-Impact Analysis 30

5.1.5 Key Stakeholders 31

6 Application: Market Size and Analysis 33

6.1 Overview 33

6.2 Asthma 34

6.3 Chronic Obstructive Pulmonary Disease (COPD) 35

6.4 Cystic Fibrosis 36

6.5 Allergic Rhinitis 37

6.6 Others 38

7 Regions: Market Size and Analysis 40

7.1 Overview 40

7.2 North America 41

7.2.1 Overview 41

7.2.2 United States 42

7.2.3 Canada 43

7.3 Europe 43

7.3.1 Overview 43

7.3.2 United Kingdom 44

7.3.3 Germany 44

7.3.4 France 45

7.4 APAC 45

7.4.1 Overview 45

7.4.2 India 45

7.4.3 China 46

7.4.4 Japan 46

7.5 Rest of the World 47

7.5.1 Overview 47

7.5.2 Middle East 48

7.5.3 Brazil 49

7.5.4 Mexico 49

8 C

Licence Rights

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Novartis AG, GlaxoSmithKline plc, Astra Zenca PLC, F.Hoffmann-La Roche Ltd. , Vertex Pharmaceuticals Inc. Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd. Gilead Sciences Inc. Bayer AG, Pfizer Inc., Bristol-Myers Squibb Co. Merck & Co., Sanofi, Mallinckrodt plc

Respiratory disorders, which affect mechanisms of the respiratory system such as the lungs and airway, are a wide-ranging chronic disease with a diversity of underlying causes, ranging from inherited mutations to pathological inflammation. The respiratory disorders market is dominated by long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapies for chronic obstructive pulmonary disease (COPD) and asthma. These drugs stimulate muscles surrounding the bronchial tubes to suppress and open the airways.

 

Respiratory therapy area consists of signs that affect the lungs, bronchi, trachea, larynx, pharynx and nose in various ways, such as the scarring of lung tissue or the extreme production of mucus. Respiratory disease generally results in breathing difficulties, that can lead to troubles in sleep, wheezing, anxiety, and stress. During worse condition, shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders contrasts significantly across each indication and comprises factors such as environment, occupation, genetic predisposition, and aging.

 

Report Scope:

 

Report Category: Pharmacuticals / Healthcare

 

Therapy Type

Asthma

Chronic Obstructive Pulmonary Disease

Idiopathic Pulmonary Fibrosis

Cystic Fibrosis

End-user

Hospitals

Ambulatory Care

Others

Regions

North America

Europe

Asia Pacific

Rest of the World

Industry Outlook: Market Trends and Drivers, Restraints, and Opportunities

READ MORE

Scope

Table of Contents

1 Industry Outlook 9

1.1 Industry Overview 9

1.2 Total Addressable Market 10

1.3 Industry Trends 10

2 Report Outline 12

2.1 Report Scope 12

2.2 Report Summary 12

2.3 Research Methodology 13

2.4 Report Assumptions 13

3 Market Snapshot 15

3.1 Market Definition-Infoholic Research 15

3.2 Segmented Addressable Market (SAM) 15

3.3 Importance of Respiratory Care 15

3.4 Trends of Respiratory Drugs Market 16

3.5 Related Markets 17

3.5.1 Oncology (Cancer) Drugs 17

3.5.2 Active pharmaceutical ingredients (APIs) 17

3.5.3 Over the counter drugs (OTC) 18

3.5.4 Diabetes Drugs 18

4 Market Outline 20

4.1 Pipeline Products of Respiratory Drugs by Major Companies 20

4.2 Market Segmentation 23

4.3 Porter 5(Five) Forces 24

4.4 PEST Analysis 25

5 Market Characteristics 26

5.1 Market Dynamics of Respiratory Drugs Market 26

5.1.1 Drivers 27

5.1.1.1 Increasing Aging Population 27

5.1.1.2 Rising prevalence of respiratory diseases 28

5.1.1.3 High prevalence of tobacco smoking 28

5.1.2 Opportunities 28

5.1.2.1 Supportive initiatives from government and other organizations 28

5.1.2.2 Huge pool of undiagnosed chronic obstructive pulmonary disease population 28

5.1.3 Restraints 29

5.1.3.1 Expiry of patents for blockbuster drugs 29

5.1.3.2 Complex drug development process 30

5.1.4 DRO-Impact Analysis 30

5.1.5 Key Stakeholders 31

6 Application: Market Size and Analysis 33

6.1 Overview 33

6.2 Asthma 34

6.3 Chronic Obstructive Pulmonary Disease (COPD) 35

6.4 Cystic Fibrosis 36

6.5 Allergic Rhinitis 37

6.6 Others 38

7 Regions: Market Size and Analysis 40

7.1 Overview 40

7.2 North America 41

7.2.1 Overview 41

7.2.2 United States 42

7.2.3 Canada 43

7.3 Europe 43

7.3.1 Overview 43

7.3.2 United Kingdom 44

7.3.3 Germany 44

7.3.4 France 45

7.4 APAC 45

7.4.1 Overview 45

7.4.2 India 45

7.4.3 China 46

7.4.4 Japan 46

7.5 Rest of the World 47

7.5.1 Overview 47

7.5.2 Middle East 48

7.5.3 Brazil 49

7.5.4 Mexico 49

8 C

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Novartis AG, GlaxoSmithKline plc, Astra Zenca PLC, F.Hoffmann-La Roche Ltd. , Vertex Pharmaceuticals Inc. Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd. Gilead Sciences Inc. Bayer AG, Pfizer Inc., Bristol-Myers Squibb Co. Merck & Co., Sanofi, Mallinckrodt plc